natgillin/translations-raw huggingface dataset:
Figur 5: Samlet overlevelse fordelt på subgrupper: hazard ratio og 95 % konfidensinterval
Figure 5: Overall survival by subgroup: hazard ratio and 95% confidence interval
Figur 5a Figure 5b
Figure 5a Figure 5b
figur 7
figure 7
Figur 7 Figur 8 Figur 9
Figure 7 Figure 8 Figure 9
Figur 8 Figur 9
Figure 8 Figure 9
Figur A
Pict ure A
Figur A Figur B Figur C Figur D
Figure A Figure B Figure C Figure D
Figur A. Figur B. Figur C.
Figure A. Figure B. Figure C.
Figur A: Bank fast for at blande
Figure A: Tap firmly to mix
Figur B: Kontroller for ikke opslæmmet pulver og gentag om nødvendigt ved at banke let.
Figure B: Check for unsuspended powder and repeat tapping if needed.
Figur B: Tryk med gaze eller vat (må ikke gnides)
Figure B: Press (don’t rub) with gauze or cotton
Figur D
aut
Figur D. Figur E. Figur F.
Figure D. Figur E. Figure F.
Figur D. Figur E. Figur F.
Figure D. Figure E. Figure F.
Figur E Figur F Figur G Figur H
Figure E Figure F Figure G Figure H
Figure 3 RADIANT-4 – Kaplan-Meier-kurver for progressionsfri overlevelse (uafhængig radiologisk vurdering)
Figure 3 RADIANT-4 – Kaplan-Meier progression-free survival curves (independent radiological review)
Figure 4 RADIANT-4 – Resultater for progressionsfri overlevelse i præ-specificerede undergrupper (uafhængig radiologisk vurdering)
Figure 4 RADIANT-4 – Progression free survival results by pre-specified patient subgroup (independent radiological review)
Fik 3 doser
Received 3 doses
fik alle 3 vaccinationer inden for 1 år efter inklusion, ikke afveg i væsentlig grad fra studieprotokollen, var seronegative over for den/de relevante HPV-type(r) (type 6, 11, 16 og 18) før dosis 1, og blandt personer på 16 år eller ældre ved inklusionen i basisstudiet, var PCR-negative over for den/de relevante HPV-type(r) før dosis 1 og til og med 1 måned efter dosis 3 (måned 7).
who received all 3 vaccinations within 1 year of enrolment, did not have major deviations from the study protocol, were seronegative to the relevant HPV type(s) (types 6, 11, 16, and 18) prior to dose 1, and among subjects 16 years and older at enrolment in the base study, were PCR negative to the relevant HPV type(s) prior to dose 1 through one month post-dose 3 (Month 7).
Fiksér dyrets hoved, løft overlæben og stik kanylen ind i overlæbens inderside indtil applikatoren hviler på læben.
Restrain the animal’s head, lift the upper lip and insert the needle into the inside of the upper lip until the applicator rests on the lip.
Filamentøs hæmagglutinin (FHA) 20 mikrogram
Filamentous Haemagglutinin (FHA) 20 micrograms
Filamentøs hæmagglutinin (FHA)1 25 mikrogram
Filamentous Haemagglutinin (FHA)1 25 micrograms
Filamentøs hæmagglutinin 25 mikrogram
Filamentous Haemagglutinin 25 micrograms
Filamentøs hæmagglutinin, adsorberet 25 mikrogram
Filamentous haemagglutinin, adsorbed 25 micrograms
Filamentøs hæmagglutinin1 25 mikrogram
Filamentous Haemagglutinin1 25 micrograms
Filgrastim bør ikke anvendes til at forhøje dosis af cytotoksisk kemoterapi ud over de etablerede dosisregimer (se nedenfor).
Filgrastim should not be used to increase the dose of cytotoxic chemotherapy beyond established dosage regimens (see below).
Filgrastim bør ikke gives til patienter med svær medfødt neutropeni, der udvikler leukæmi eller har evidens for leukæmisk evolution.
Filgrastim should not be administered to patients with severe congenital neutropenia who develop leukaemia or have evidence of leukaemic evolution.
Filgrastim bør seponeres permanent hos patienter, som får alvorlige allergiske reaktioner.
Filgrastim should be permanently discontinued in patients who experience a serious allergic reaction.
Filgrastim dosisjustering
Filgrastim dose adjustment
Filgrastim er et rekombinant methionyl human granulocytkolonistimulerende faktor produceret i
Filgrastim is a recombinant methionyl human granulocyte-colony stimulating factor produced in
Filgrastim er indiceret til behandling af persisterende neutropeni (ANC mindre end eller lig med 1,0 x 109 /l) hos patienter med fremskreden HIV-infektion for at nedsætte risikoen for bakterielle infektioner, hvis der ikke er andre egnede behandlinger.
Filgrastim is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109 /l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.
Filgrastim er indiceret til langtidsbehandling af børn og voksne med svær medfødt, cyklisk eller idiopatisk neutropeni med et absolut neutrofiltal (ANC) på ≤ 0,5 x 109/l og alvorlige eller tilbagevendende infektioner i anamnesen for at øge neutrofiltallet og reducere forekomsten og varigheden af infektionsrelaterede hændelser.
In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/l, and a history of severe or recurrent infections, long term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
Filgrastim er indiceret til mobilisering af perifere blodprogenitorceller (PBPC’er).
Filgrastim is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs).
Filgrastim gives som en intravenøs, kortvarig infusion over 30 minutter eller som en subkutan eller intravenøs, kontinuerlig infusion over 24 timer i hvert tilfælde efter fortynding i 20 ml 50 mg/ml (5 %) isoton glukose til infusion.
Filgrastim is administered as an intravenous short-term infusion over 30 minutes or as a subcutaneous or intravenous continuous infusion over 24 hours, in each case after dilution in 20 ml of glucose 50 mg/ml (5%) solution.
Filgrastim HEXAL 30 mill.
SUMMARY OF PRODUCT CHARACTERISTICS
Filgrastim HEXAL anvendes til at behandle børn, som får kemoterapi, eller som har et antal hvide blodlegemer, som er svært nedsat (neutropeni).
Filgrastim HEXAL is used to treat children who are receiving chemotherapy or who suffer from severe low white blood cell count (neutropenia).
Filgrastim HEXAL bør ikke anvendes under graviditet.
Filgrastim HEXAL is not recommended during pregnancy.
Filgrastim HEXAL er en klar, farveløs til let gullig opløsning til injektion eller infusion i fyldt injektionssprøjte.
Filgrastim HEXAL is a clear, colourless to slightly yellowish solution for injection or infusion in pre-filled syringe.
Filgrastim HEXAL er en vækstfaktor for hvide blodlegemer (granulocyt-kolonistimulerende faktor) og tilhører en gruppe proteiner ved navn cytokiner.
Filgrastim HEXAL is a white blood cell growth factor (granulocyte colony stimulating factor) and belongs to a group of proteins called cytokines.
Filgrastim Hexal er et »biosimilært« lægemiddel.
Filgrastim Hexal is a ‘biosimilar’ medicine.
Filgrastim HEXAL indeholder r-metHuG-CSF (filgrastim) og forårsager udtalte stigninger i neutrofiltallene inden for 24 timer ledsaget af en mindre stigning i antallet af monocytter.
Filgrastim HEXAL containing r-metHuG-CSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes.
Filgrastim HEXAL leveres med eller uden kanylebeskyttelse, og læge eller sundhedspersonalet viser dig, hvordan du anvender den.
Filgrastim HEXAL is provided with or without a needle safety guard and you will be shown how to use this by your doctor or nurse.
Filgrastim HEXAL påvirker sandsynligvis ikke evnen til at føre motorkøretøj og betjene maskiner.
Filgrastim HEXAL should not affect your ability to drive and use machines.
Filgrastim HEXALs stabilitet ændres ikke, selvom det ved et uheld bliver udsat for temperaturer under frysepunktet.
Accidental exposure to freezing temperatures does not adversely affect the stability of Filgrastim HEXAL.
Filgrastim i Accofil fremstilles ved “rekombinant DNA-teknologi”: Det produceres af bakterier, der har fået indsat et gen (DNA), som gør dem i stand til at producere filgrastim.
The filgrastim in Accofil is produced by a method known as ‘recombinant DNA technology’: it is made by bacteria into which a gene (DNA) has been introduced that makes them able to produce filgrastim.
Filgrastim i Grastofil fremstilles ved »rekombinant DNA-teknologi«: Det produceres af bakterier, der har fået indsat et gen (DNA), som gør dem i stand til at producere filgrastim.
The filgrastim in Grastofil is produced by a method known as ‘recombinant DNA technology’: it is made by bacteria into which a gene (DNA) has been introduced that makes them able to produce filgrastim.
Filgrastim kan gives som en 24-timers subkutan kontinuerlig infusion eller som en subkutan injektion.
Filgrastim may be given as a 24 hour subcutaneous continuous infusion or subcutaneous injection.
Filgrastim kan gives som en daglig subkutan injektion eller som en daglig intravenøs infusion fortyndet med 5% glucoseinfusionsvæske og givet over 30 minutter (se pkt.
Filgrastim may be given as a daily subcutaneous injection or as a daily intravenous infusion diluted in 5% glucose solution given over 30 minutes (see section 6.6).
Filgrastim kan gives som en daglig, subkutan injektion eller som en daglig, intravenøs infusion fortyndet i glucoseinfusionsvæske, opløsning 50 mg/ml (5 %) givet over 30 minutter (se pkt.
Filgrastim may be given as a daily subcutaneous injection or as a daily intravenous infusion diluted in glucose 50 mg/ml (5%) solution for infusion given over 30 minutes (see section 6.6 for instructions on dilutions).
Filgrastim må ikke gives til patienter med svær medfødt neutropeni, som udvikler leukæmi, eller hvor der er bevis for leukæmisk evolution.
Filgrastim should not be administered to patients with severe congenital neutropenia who develop leukaemia or have evidence of leukaemic evolution.
Filgrastim produceres via en metode, der er kendt som ‘rekombinant DNA-teknologi’: Det produceres af en bakterie, der har modtaget et gen (DNA), som gør den i stand til at producere filgrastim.
Filgrastim is produced by a method known as ‘recombinant DNA technology’: it is made by a bacterium that has received a gene (DNA), which makes it able to produce filgrastim.
Filgrastim påvirker i mindre eller ubetydelig grad evnen til at føre motorkøretøj eller betjene maskiner.
Filgrastim has minor or moderate influence on the ability to drive and use machines.
Filgrastim ratiopharm 48 mio.IE/0,8 ml injektions- og infusionsvæske, opløsning
Filgrastim ratiopharm 48 MIU/0.8 ml solution for injection or infusion
Filgrastim ratiopharm anvendes til at stimulere dannelsen af hvide blodlegemer i følgende tilfælde:
Filgrastim ratiopharm is used to stimulate the production of white blood cells in the following situations:
Filgrastim ratiopharm blev undersøgt for at påvise, at det er sammenligneligt med referencelægemidlet Neupogen.
Filgrastim ratiopharm was studied to show that it is comparable to the reference medicine, Neupogen.
Filgrastim ratiopharm bør ikke anvendes hos patienter, der kan være overfølsomme (allergiske) over for filgrastim eller andre af indholdsstofferne.
Filgrastim ratiopharm should not be used in people who may be hypersensitive (allergic) to filgrastim or any of the other ingredients.
Filgrastim ratiopharm bør ikke fortyndes i natriumklorid.
Filgrastim ratiopharm should not be diluted with sodium chloride solution.
Filgrastim ratiopharm er en injektions- og infusionsvæske i en fyldt injektionssprøjte.
Filgrastim ratiopharm is a solution for injection or infusion in a pre-filled syringe.
Filgrastim ratiopharm er et ‘biosimilært’ lægemiddel.
Filgrastim ratiopharm is a ‘biosimilar’ medicine.
Filgrastim ratiopharm indeholder ikke konserveringsmiddel.
Filgrastim ratiopharm does not contain any preservative.
Filgrastim ratiopharm kan fortyndes efter behov med 50 mg/ml (5 %) glucose infusionsvæske.
If required, Filgrastim ratiopharm may be diluted in glucose 50 mg/ml (5%) solution for infusion .
Filgrastim ratiopharm og alvorlig lav mængde af hvide blodlegemer (kronisk neutropeni)
Filgrastim ratiopharm and severe chronic neutropenia
Filgrastim ratiopharm og forøget dannelse af stamceller i blodet (mobilisering af perifere blodstamceller)
Filgrastim ratiopharm and peripheral blood stem cell mobilisation
Filgrastim ratiopharm og kemoterapi
Filgrastim ratiopharm and chemotherapy
Filgrastim ratiopharm og knoglemarvstransplantation
Filgrastim ratiopharm and bone marrow transplantation
Filgrastim ratiopharm og lav mængde af hvide blodlegemer (neutropeni) hos patienter med hiv- infektion
Filgrastim ratiopharm and neutropenia in patients with HIV infection
Filgrastim s.c./i.v.
Filgrastim SC/IV
Filgrastim skal fortyndes i 20 ml 5% glucoseinfusionsvæske (se pkt.
Filgrastim should be diluted in 20 ml of 5% glucose solution (see section 6.6).
Filgrastim skal fortyndes i 20 ml glucoseinfusions- væske, opløsning 50 mg/ml (5 %) (se pkt.
Filgrastim should be diluted in 20 ml of 50 mg/ml (5%) glucose solution for infusion (see section 6.6).
Filgrastim skal gives ved subkutan injektion.
Filgrastim should be given by subcutaneous injection.
Filgrastim skal seponeres permanent hos patienter, der oplever en alvorlig allergisk reaktion.
Filgrastim should be permanently discontinued in patients who experience a serious allergic reaction.
Filgrastim til PBPC mobilisering efter myelosuppressiv kemoterapi: Filgrastim bør gives som subkutan injektion.
Filgrastim for PBPC mobilisation after myelosuppressive chemotherapy: Filgrastim should be given by subcutaneous injection.
Filgrastim virker primært på neutrofile precursor-celler, og resulterer i forhøjede neutrofiltal.
Filgrastim acts primarily on neutrophil precursors to exert its effect in elevating neutrophil counts.
Filgrastim virker på samme måde som naturligt dannet G-CSF ved at stimulere knoglemarven til at producere flere hvide blodlegemer.
Filgrastim acts in the same way as naturally produced G-CSF by encouraging the bone marrow to produce more white blood cells.
Filgrastimet i Lonquex fremstilles ved “rekombinant DNA-teknologi”: Det produceres ved dyrkning af bakterier, der har fået indsat et gen (DNA), som gør dem i stand til at producere filgrastim-proteinet.
The filgrastim in Lonquex is produced by a method known as ‘recombinant DNA technology’: it is made by bacteria into which a gene (DNA) has been introduced that makes the bacteria able to produce the filgrastim protein.
Filgrastims eliminationshalveringstid er ca.
The serum elimination half-life of filgrastim is approximately
Filgrastims sikkerhed og effekt er ikke undersøgt hos raske donorer < 16 år eller > 60 år.
The safety and efficacy of filgrastim have not been assessed in normal donors < 16 years or > 60 years.
Filgrastims sikkerhed og virkning hos de novo patienter med AML, som er under 55 år, og som har god cytogenetik [t(8;21), t(15;17) og inv(16)], er ikke dokumenteret.
The safety and efficacy of filgrastim administration in de novo AML patients aged < 55 years with good cytogenetics [t(8;21), t(15;17), and inv(16)] have not been established.
Filgrastims sikkerhed og virkning hos patienter med myelodysplastisk syndrom eller kronisk myeloid leukæmi er ikke klarlagt.
The safety and efficacy of filgrastim administration in patients with myelodysplastic syndrome or chronic myelogenous leukaemia have not been established.
Filgrastims sikkerhedsprofil i disse studier var konsistent med sikkerhedsprofilen for de referencepræparater, som blev brugt i studierne.
The safety profile of filgrastim observed in these clinical studies was consistent with that reported with the reference product used in these studies.
Film-overtrukne tabletter
Film-coated tablet
Filmomhulde tablet
Film-coated tablet
Filmomhulde tablet.
Film-coated tablet.
Filmovertrukken
Film-coated tablet
Filmovertrukken tablet
Film-coated tablet Film-coated tablet
Filmovertrukken tablet
Film-coated tablet.
Filmovertrukken tablet
tablet tablet
Filmovertrukken tablet (tabletter) Briviact 10 mg filmovertrukne tabletter
Film-coated tablet (tablets) Briviact 10 mg film-coated tablets
Filmovertrukken tablet (tabley)
Film-coated tablet (tablet).
Filmovertrukken tablet Oral anvendelse Blister (PVC/alu) i
Film-coated tablet Oral use blister (PVC/alu) in
Filmovertrukken tablet.
Film-coated tablet (tablet)
Filmovertrukken, hvid, aflang tablet med TMC trykt på den ene side og 75 på den anden side.
Film-coated, white, caplet shaped tablet, mentioning TMC on one side, 75 on the other side.
Filmovertrukken, hvid, oval tablet med TMC trykt på den ene side og 150 på den anden side.
Film-coated, white, oval shaped tablet, mentioning TMC on one side, 150 on the other side.
Filmovertrukken, lys orange, oval tablet med TMC trykt på den ene side og 400MG på den anden side.
Film-coated, light orange, oval shaped tablet, mentioning TMC on one side, 400MG on the other side.
Filmovertrukken, mørkerød, oval tablet med T trykt på den ene side og 800 på den anden side.
Film-coated, dark red, oval shaped tablet, mentioning T on one side, 800 on the other side.
Filmovertrukken, orange, oval tablet med TMC trykt på den ene side og 600MG på den anden side.
Film-coated, orange, oval shaped tablet, mentioning TMC on one side, 600MG on the other side.
Filmovertrukken, orange, oval tablet med TMC114 trykt på den ene side og 300MG på den anden side.
Film-coated, orange, oval shaped tablet, mentioning TMC114 on one side, 300MG on the other side.
Filmovertrukket
EU/1/09/551/015
Filmovertrukket
Film-coated tablet
Filmovertrukket
Film-coated tablet Film-coated tablet
Filmovertrukket
Route of
Filmovertrukket (tablet)
Film-coated (tablet)
Filmovertrukket tablet
Film-coated
Filmovertrukket tablet
Film-coated tablet Film-coated tablet
Filmovertrukket tablet
Film-coated tablet Film-coated tablet Film-coated tablet
Filmovertrukket tablet
Film-coated tablets
Filmovertrukket tablet (tablet).
Film-coated tablet (tablets).
Filmovertrukket tablet (tablet).
Film-coated tablet.
Filmovertrukket tablet (tablet): Tabletterne er runde, bikonvekse, gule, filmovertrukne, præget med "90" over "T" på den ene side.
Film-coated tablet (tablet): The tablets are round, biconvex, yellow, film-coated marked with a “90” above “T” on one side.
Filmovertrukket tablet (tablet): Tabletterne er runde, bikonvekse, pink, filmovertrukne, præget med "60" over "T" på den ene side.
Film-coated tablet (tablet): The tablets are round, biconvex, pink, film-coated marked with a “60” above “T” on one side.
Filmovertrukket tablet (tabletter): STAYVEER 62,5 mg filmovertrukne tabletter
Film-coated tablet (tablets): STAYVEER 62.5 mg film-coated tablets
Filmovertrukket tablet 50 mg:
Film-coated tablet 50 mg:
Filmovertrukket tablet [tablet].
Film-coated tablet [tablet].
Filmovertrukket tablet Amlodipine/Valsartan Mylan 5 mg/80 mg filmovertrukne tabletter
Film-coated tablet Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets
Filmovertrukket tablet Filmovertrukket tablet blister (Aclar/PVC/alu)
Film-coated tablet Film-coated tablet Film-coated tablet
Filmovertrukket tablet Wakix 4,5 mg filmovertrukken tablet
Film-coated tablet Wakix 4.5 mg film-coated tablet
Filmovertrukket tablet: gul, kapselformet, filmovertrukket tablet præget med ”Teva” på den ene side og ”7541” på den anden
Film-coated tablet: yellow, capsule-shaped, film-coated tablet debossed with “Teva” on one side and “7541” on the other
Filmovertrukket tablett
Film-coated tablet
Filmovertrukne
Film-coated tablet
Filmovertrukne aktive tabletter: hvide, runde og mærket 'ne' på begge sider.
Active film-coated tablets: white, round and coded ‘ne’ on both sides.
Filmovertrukne placebo-tabletter: gule, runde og mærket 'p' på begge sider.
Placebo film-coated tablets: yellow, round and coded ‘p’ on both sides.
Filmovertrukne tabletter
Film coated tablets
Filmovertrukne tabletter
Film-coated tablet (tablet)
Filmovertrukne tabletter
Film-coated tablet Film-coated tablet
Filmovertrukne tabletter
Film-coated tablet.
Filmovertrukne tabletter
Film-coated tablets.
Filmovertrukne tabletter
IF APPROPRIATE
Filmovertrukne tabletter .
Film-coated tablet.
Filmovertrukne tabletter 1 filmovertrukken tablet
Film-coated tablets 1 film-coated tablet
Filmovertrukne tabletter 100 filmovertrukne tabletter
Film-coated tablets 100 film-coated tablets
Filmovertrukne tabletter 3 filmovertrukne tabletter
Film-coated tablets 3 film-coated tablets
filmovertrukne tabletter filmovertrukne tabletter
film-coated tablets film-coated tablets
Filmovertrukne tabletter og infusionsvæske, opløsning
Film-coated tablets and solution for infusion
Filmovertrukne tabletter og pulver til oral suspension
Film-coated tablets and powder for oral suspension
Filmovertrukne tabletter STOCRIN 600 mg filmovertrukne tabletter
Film-coated tablet STOCRIN 600 mg film-coated tablets
Filmovertrukne tabletter Vareniclin
Film-coated tablets Varenicline
Filmovertrukne tabletter.
Film coated tablet.
Filmovertrukne tabletter.
Film coated tablets.
Filmovertrukne tabletter.
Film-coated tablet (tablets)
Filmovertrykket tablet
Film-coated tablet
Filmovertræk
Film coat
Filmovertræk
Film-coating:
Filmovertræk
Sodium lauryl sulfate
Filmovertræk
Tablet film-coat
Filmovertræk (2 mg, 4 mg, 6 mg, 8 mg, 10 mg og 12 mg tabletter) Hypromellose 2910, talcum, macrogol 8000, titandioxid (E171), farvestoffer*
Film coating (2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg tablets) Hypromellose 2910, talc, Macrogol 8000, titanium dioxide (E171), colourants
Filmovertræk (gule filmovertrukne placebo-tabletter) Poly(vinyl alkohol) (E1203)
Tablet coating (yellow placebo film-coated tablets) Poly(vinyl alcohol) (E1203)
Filmovertræk (hvide aktive filmovertrukne tabletter) Poly(vinyl alkohol) (E1203)
Tablet coat (white active film-coated tablets) Poly(vinyl alcohol) (E1203)
Filmovertræk (hvide aktive filmovertrukne tabletter) Poly(vinyl alkohol) (E1203)
Tablet coating (white active film-coated tablets) Poly(vinyl alcohol) (E1203)
Filmovertræk (Opadry lyserød OY-L-24802): Hypromellose 6cP
Film coating (Opadry pink OY-L-24802): Hypromellose 6cP
Filmovertræk - hypromellose (hydroxypropylmethylcellulose, E464), titandioxid (E171), talcum (E553b), triacetin (E1518), rød iron jernoxid (E172)
Film-coating - hypromellose (hydroxypropyl methyl cellulose, E464), titanium dioxide (E171), talc (E553b), triacetin (E1518), red iron oxide (E172)
Filmovertræk af tablet: macrogol 3350, hypromellose, titandioxid (E 171), gul jernoxid (E 172).
Tablet film coat: macrogol 3350, hypromellose, titanium dioxide (E 171), iron oxide yellow (E 172).
Filmovertræk Betmiga 25 mg depottabletter Hypromellose
Film coating Betmiga 25 mg prolonged-release tablets Hypromellose
Filmovertræk Betmiga 50 mg depottabletter Hypromellose
Film coating Betmiga 50 mg prolonged-release tablets Hypromellose
Filmovertræk Ethylcellulose Hypromellose Macrogol 8000 Triethyl citrat Titanium dioxid Talkum
Film-coating Ethylcellulose Hypromellose Macrogol 8000 Triethyl citrate Titanium dioxide Talc
Filmovertræk for styrken 150 mg/12,5 mg: Hypromellose
Film-coating for 150 mg/12.5 mg strength: Hypromellose
Filmovertræk for styrken 300 mg/12,5 mg: Hypromellose
Film-coating for 300 mg/12.5 mg strength: Hypromellose
Filmovertræk for styrken 300 mg/25 mg: Hypromellose
Film coating for 300 mg/25 mg strength: Hypromellose
Filmovertræk Hypromellose
Film-coating Hypromellose
Filmovertræk Hypromellose Lactosemonohydrat Triacetin
Film-coating Hypromellose Lactose monohydrate Triacetin
Filmovertræk Hypromellose Macrogol 4000 Talcum
Coating Hypromellose Macrogol 4000 Talc
Filmovertræk Hypromellose Macrogol 4000 Talcum Titandioxid (E171)
Coating Hypromellose Macrogol 4000 Talc
Filmovertræk Hypromellose Macrogol 8000 Titaniumdioxid Talkum
Film coating Hypromellose Macrogol 8000 Titanium dioxide Talc
Filmovertræk Hypromellose Macrogol Talcum
Coating Hypromellose Macrogol Talc
Filmovertræk Hypromellose Titandioxid (E 171)
Coating Hypromellose
Filmovertræk Hypromellose Titandioxid Macrogol 400
Film-coating Hypromellose Titanium dioxide Macrogol 400
Filmovertræk Hypromellose Titandioxid Macrogol 400
Tablet film coat Hypromellose Titanium dioxide Macrogol 400
Filmovertræk Hypromellose Titandioxid Triacetin
Film-coating Hypromellose Titanium Dioxide Triacetin
Filmovertræk Poly(vinylalkohol) Macrogol 3350 Talcum (E553b) Titandioxid (E171) Rød jernoxid (E172) Sort jernoxid (E172)
Film coating poly(vinyl alcohol) macrogol 3350 talc (E553b) titanium dioxide (E171) iron oxide red (E172) iron oxide black (E172)